COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
31 hedge funds and large institutions have $1.46M invested in COSCIENS Biopharma Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 4 closing their positions.
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
5% less call options, than puts
Call options by funds: $473K | Put options by funds: $498K
9% less funds holding
Funds holding: 34 → 31 (-3)
16% less capital invested
Capital invested by funds: $1.74M → $1.46M (-$282K)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$164K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$94.3K |
| 3 |
N
Natixis
Paris,
France
|
+$50.2K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$27.3K |
| 5 |
Squarepoint
New York
|
+$7.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$214K |
| 2 |
Goldman Sachs
New York
|
-$58.7K |
| 3 |
VF
Virtu Financial
New York
|
-$57.2K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$44.2K |
| 5 |
JP Morgan Chase
New York
|
-$12.4K |
CSCI Hedge Fund Activity: Q3 2021 in Review
31 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q3 2021, worth a combined $1.46M — down 16% from $1.74M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CSCI and 1 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Renaissance Technologies, adding an estimated $164K. The largest seller was Sabby Management, exiting entirely with an estimated $214K sold.
- 31 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q3 2021, down from 34 in Q2 2021.
- Funds reported $1.46M of COSCIENS Biopharma Inc. Common Stock stock for Q3 2021, down 16% quarter-over-quarter.
- 1 fund opened new COSCIENS Biopharma Inc. Common Stock positions in Q3 2021 and 4 closed out, a net change of -3 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q3 2021 was Renaissance Technologies, an estimated $164K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q3 2021 was Sabby Management, an estimated $214K sold.
Based on aggregated 13F filings for Q3 2021.